Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 109, Issue 2, Pages 352-366Publisher
WILEY
DOI: 10.1002/cpt.1973
Keywords
-
Categories
Funding
- National Institutes of Health [R24 GM123930]
- PharmGKB [U24 HG010615]
- Implementing Genomics in Practice (IGNITE) project grant [U01 HG010245]
- NIH/NIMHD [U54 MD007600-33]
Ask authors/readers for more resources
This article introduces the star (*) allele nomenclature for the polymorphic human CYP2C19 gene catalogued by PharmVar, and highlights the impact of CYP2C19 genetic variation on drug metabolism, as well as how haplotype information compiled by PharmVar is utilized by CPIC.
The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele nomenclature for the polymorphic human CYP2C19 gene. CYP2C19 genetic variation impacts the metabolism of many drugs and has been associated with both efficacy and safety issues for several commonly prescribed medications. This GeneFocus provides a comprehensive overview and summary of CYP2C19 and describes how haplotype information catalogued by PharmVar is utilized by the Pharmacogenomics Knowledgebase and the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
